Latest Interim Results News

The GPT Group reported a solid first half in 2026, posting 5% growth in funds from operations and expanding its assets under management to $41.6 billion. Major development projects and capital initiatives underpin its steady momentum.

Avecho Biotechnology has secured a unanimous recommendation to continue its Phase III insomnia trial without increasing sample size, alongside raising $1.9 million through option exercises and bolstering its cash position to $6.6 million.

Adherium Limited has posted a fourth consecutive quarter of record remote patient monitoring revenue, driven by growing device activations and strong clinical evidence from the iCARE study, positioning the company for expanded value-based care contracts in the US.

LTR Pharma’s SPONTAN shows rapid absorption in Phase II interim data while securing key US commercial deals for ROXUS, setting the stage for a US market entry later this year.

Chimeric Therapeutics reports encouraging interim data from its Phase 1/2 trial of CHM CDH17 CAR-T therapy, with tumour shrinkage up to 40% and stable disease maintained for months at the highest dose level.

GPT Group has declared an estimated 12.25 cents per stapled security distribution for the first half of 2026, marking a modest increase from prior payouts as it prepares to release interim financial results in August.

OncoSil Medical has secured a pivotal ethics committee approval in Italy, reclassifying its OSPRItaly registry and enabling a streamlined procurement process that could double the number of authorised hospitals using its OncoSil™ device by mid-2027.

South Port New Zealand is navigating a significant leadership transition with CEO Nigel Gear stepping down after 8.5 years, replaced by port veteran Derek Nind, while Chair Philip Cory-Wright plans retirement. The company reports strong trading momentum, aiming for a record full year despite geopolitical uncertainties.

OncoSil Medical has clinched TGA approval for its OncoSil™ device, the first Class III medical device targeting pancreatic tumours in Australia, paving the way for local commercialisation and enhanced patient access.

Laramide Resources posted a CAD 1.13 million net loss for Q1 2026, reflecting ongoing exploration costs and a one-off loss from exiting its Kazakhstan asset. The company’s mineral property base expanded to CAD 118.7 million, driven by Australian and US projects.

OncoSil Medical’s interim OSPREY Registry data show strong safety and promising survival outcomes for its targeted radiotherapy device in unresectable locally advanced pancreatic cancer, surpassing historical benchmarks.

AVITA Medical reported a 4% revenue increase in Q1 2026 with a narrowed net loss, underpinned by a new BARDA contract and promising Cohealyx clinical data. Leadership changes and regulatory approvals support a confident outlook.